Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.781364
Keywords
Tregs; CLL; E mu-TCL1; MALT1; TCR repertoire; anti-leukemic immune response
Categories
Funding
- Polish National Science Centre [2018/29/B/NZ6/01962, 2016/21/B/NZ7/02041]
- Ministry of Science and Higher Education within Regional Initiative of Excellence program in the years 2019-2022 [013/RID/2018/19]
- FNRS Televie [7.6518.20]
- Fonds National de la Recherche Luxembourg [TIME-CLL: C20/BM/14582635]
Ask authors/readers for more resources
Regulatory T cells (Tregs) play an important role in chronic lymphocytic leukemia (CLL) by inhibiting the activation and function of T cells, affecting the immune response. This study identified a specific Tregs subpopulation in CLL with a phenotype and gene expression profile supportive of leukemia survival and proliferation. Tregs depletion triggered the expansion of anti-leukemic cytotoxic T cell clones, leading to leukemia eradication. In addition, inhibiting Tregs showed therapeutic benefits in CLL treatment, either as monotherapy or in combination with an immune checkpoint inhibitor.
Regulatory T cells (Tregs) are capable of inhibiting the proliferation, activation and function of T cells and play an important role in impeding the immune response to cancer. In chronic lymphocytic leukemia (CLL) a dysfunctional immune response and elevated percentage of effector-like phenotype Tregs have been described. In this study, using the E mu-TCL1 mouse model of CLL, we evaluated the changes in the Tregs phenotype and their expansion at different stages of leukemia progression. Importantly, we show that Tregs depletion in DEREG mice triggered the expansion of new anti-leukemic cytotoxic T cell clones leading to leukemia eradication. In TCL1 leukemia-bearing mice we identified and characterized a specific Tregs subpopulation, the phenotype of which suggests its role in the formation of an immunosuppressive microenvironment, supportive for leukemia survival and proliferation. This observation was also confirmed by the gene expression profile analysis of these TCL1-specific Tregs. The obtained data on Tregs are consistent with those described so far, however, above all show that the changes in the Tregs phenotype described in CLL result from the formation of a specific, described in this study Tregs subpopulation. In addition, functional tests revealed the ability of Tregs to inhibit T cells that recognize model antigens expressed by leukemic cells. Moreover, inhibition of Tregs with a MALT1 inhibitor provided a therapeutic benefit, both as monotherapy and also when combined with an immune checkpoint inhibitor. Altogether, activation of Tregs appears to be crucial for CLL progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available